Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 83.4%

Neg 0% Neu 0% Pos 83.4%

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.